Neurological Surgery 脳神経外科41巻9号

2013年09月発行

総説

脳神経領域での最新の抗凝固療法

著者： 矢坂正弘¹

所属機関： ¹国立病院機構九州医療センター脳血管センター脳血管・神経内科

ページ範囲：P.755 - P.764

Ⅰ．はじめに

　脳神経領域における抗凝固療法のよい適応疾患として，心原性脳塞栓症，脳静脈洞血栓症，および抗リン脂質抗体症候群などが挙げられる．本稿では新規経口抗凝固薬（novel oral anticoagulants：NOAC）の登場を受けて，非弁膜症性心房細動に伴う脳梗塞の再発予防におけるNOACの位置づけや，抗凝固療法と抗血小板療法の併用療法における最近の話題を中心に概説する．

参考文献

1) Ardekian L, Gaspar R, Peled M, Brener B, Laufer D：Does low-dose aspirin therapy complicate oral surgical procedures? J Am Dent Assoc 131：331-335, 2000

2) Blacker DJ, Wijdicks EFM, McClelland RL：Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 61：964-968, 2003

3) Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH：Guidelines for the management of atrial fibrillation：the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology（ESC). Eur Heart J 31：2369-2429, 2010

4) Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L；RE-LY Steering Committee and Investigators：Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361：1139-1151, 2009 and Erratum in：N Engl J Med 363：1877, 2010

5) Dewilde W, Oirbans T, Verheugt F, Kelder J, De Smet B, Herrman JP, Adriaenssens T, Vrolix M, Heestermans A, Vis M, Rasoul S, Sheikjoesoef K, Vandendriessche T, Van Mieghem C, Cornelis K, Vos J, Brueren G, Breet N, ten Berg J：The WOEST Trial：First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Lancet（in press）

6) Drake TA, Morrissey JH, Edgington TS：Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134：1087-1097, 1989

7) Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ：Consensus Document：Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 106：572-584, 2011

8) Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L；ARISTOTLE Committees and Investigators：Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365：981-992, 2011

9) Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S：Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran：the RE-LY trial. Stroke 43：1511-1517, 2012

10) Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M；J-ROCKET AF study investigators：Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study-. Circ J 76：2104-2111, 2012

11) Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J：Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87 Suppl 1：S141-S145, 2012

12) 日本脳卒中学会 脳卒中医療向上・社会保険委員会rt-PA（アルテプラーゼ）静注療法指針改訂部会：rt-PA（アルテプラーゼ）静注療法 適正治療指針 第二版http://www.jsts.gr.jp/img/rt-PA02.pdf

13) Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, Kamakura S, Kumagai K, Mitamura H, Okumura K, Sugi K, Yamashita T：Antithrombotic therapy in atrial fibrillation：evaluation and positioning of new oral anticoagulant agents. Circ J 75：1539-1547, 2011

14) Ogawa S, Hori M：Urgent statement on antithrombotic therapy of atrial fibrillation. Circ J 75：2719-2721, 2011

15) Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ；RE-LY Investigators：Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score：a subgroup analysis of the RE-LY trial. Ann Intern Med 155：660-667, 2011

16) 大村剛史，池上幸三郎，堀　克彦，エンスィーナス ジェフリー，丸山征郎：抗凝固薬ダビガトランエテキシラートのA-Vシャントモデルにおける抗血栓および出血に対する作用ならびに抗血栓作用に対するビタミンKの影響．Pharma Medica 29：137-142, 2011

17) Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM；the ROCKET AF Investigators：Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365：883-891, 2011

18) Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI：Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 104：642-649, 2010

19) Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K；Bleeding with Antithrombotic Therapy（BAT）Study Group：Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease：a prospective, multicenter, observational study. Stroke 39：1740-1745, 2008

20) Wahl MJ：Dental surgery in anticoagulated patients. Arch Intern Med 158：1610-1616, 1998

21) Yasaka M, Naritomi H, Minematsu K：Ischemic stroke associated with brief cessation of warfarin. Thromb Res 118：290-293, 2006

22) Yasaka M：Current strategy for anticoagulation therapy for patients with non-valvular atrial fibrillation. J Arrhythmia 28：324-329, 2012

23) Yasaka M：J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan. Circ J 76：2086-2087, 2012

24) 矢坂正弘：5．心房細動に対する抗凝固療法（2）新規経口抗凝固薬の特徴と注意点1）．直接トロンビン阻害薬（ダビガトラン）．日本臨牀71：113-118, 2013